Reporting owner · CIK 0001445826

Epstein David R

SEC Form 4 history for the last 180 days across 2 companies, 14 transactions and 7 filings.

DIRAgomAb Therapeutics NV
Open-market transaction mix92% buys12 buys · 1 sale

Period: Last 180 days

Trade dates in this period: May 21, 2026 – Nov 13, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings7Form 4 records
Buying$412k12 purchases
Selling$27.5k1 sale
Net value+$384kBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Epstein David R transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
AGMBAgomAb Therapeutics NV
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$29.9kView disclosure →
AGMBAgomAb Therapeutics NV
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$28.8kView disclosure →
AGMBAgomAb Therapeutics NV
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$120View disclosure →
AGMBAgomAb Therapeutics NV
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$30.0kView disclosure →
AGMBAgomAb Therapeutics NV
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$34.9kView disclosure →
AGMBAgomAb Therapeutics NV
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$34.6kView disclosure →
AGMBAgomAb Therapeutics NV
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$34.1kView disclosure →
TEMTempus AI, Inc.
Director
DIR
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$27.5kView disclosure →
AGMBAgomAb Therapeutics NV
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$44.5kView disclosure →
AGMBAgomAb Therapeutics NV
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$44.3kView disclosure →
AGMBAgomAb Therapeutics NV
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$44.5kView disclosure →
AGMBAgomAb Therapeutics NV
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$43.5kView disclosure →
AGMBAgomAb Therapeutics NV
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
SEC filing ↗
$42.9kView disclosure →
TEMTempus AI, Inc.
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
SEC filing ↗
$0View disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a buy at AgomAb Therapeutics NV on Nov 13, 2026 valued at $29,859.20.

Review SEC filing
Latest sale

The insider reported a sale at Tempus AI, Inc. on Nov 2, 2026 valued at $27,487.30.

Review SEC filing

Monthly open-market activity

Last 3 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
May 202600$0$0$0
Oct 202650$219,650$0+$219,650
Nov 202671$192,179.20$27,487.30+$164,691.90

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$33.8k
Median P/S size$34.6k
Direct14
Indirect0
Nov 13, 2026buy

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

12 observations · Oct 5, 2026 – Nov 13, 2026. Window ends at the latest available report, not today.

Selected observation · Nov 13, 202654,980 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Oct 5, 20265,000Oct 7, 2026View transaction
Oct 6, 202610,000Oct 7, 2026View transaction
Oct 8, 202615,000Oct 9, 2026View transaction
Oct 21, 202620,000Oct 22, 2026View transaction
Oct 21, 202625,000Oct 22, 2026View transaction
Nov 5, 202630,000Nov 6, 2026View transaction
Nov 5, 202635,000Nov 6, 2026View transaction
Nov 5, 202640,000Nov 6, 2026View transaction
Nov 13, 202645,000Nov 16, 2026View transaction
Nov 13, 202645,020Nov 16, 2026View transaction
Nov 13, 202650,020Nov 16, 2026View transaction
Nov 13, 202654,980Nov 16, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Epstein David R Insider Activity FAQ

SEC Form 4 context

Who is Epstein David R?

Epstein David R is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001445826.

Which companies has Epstein David R reported transactions for?

AgomAb Therapeutics NV, Tempus AI, Inc.

When was Epstein David R's latest insider buy?

The insider reported a buy at AgomAb Therapeutics NV on Nov 13, 2026 valued at $29,859.20.

When was Epstein David R's latest insider sale?

The insider reported a sale at Tempus AI, Inc. on Nov 2, 2026 valued at $27,487.30.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.